相关实验视频

Updated: Jan 9, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

用anifrolumab成功治疗严重的系统性红斑狼:一个单中心观察性研究

Małgorzata Wisłowska¹, Piotr Szczęsny¹, Jakub Wroński¹

¹Department of Rheumatology, National Institute Geriatric, Rheumatology and Rehabilitation, Warsaw, Poland.

|December 5, 2025

概括

在现实环境中,阿尼弗罗卢马布 (ANF) 在患有严重全身性红斑狼 (SLE),包括神经精神病性SLE和狼性炎的患者中显示出显著的临床改善. 这表明ANF是严重的SLE病例的安全和有效的治疗选择,这些病例对以前的治疗没有反应.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
临床药理学临床药理学

背景情况:

系统性红斑狼 (SLE) 是一种慢性自身免疫性疾病,具有多样化和严重的表现.
患有严重SLE的患者,包括神经精神病性SLE (神经SLE),狼性炎和与抗脂综合征相关的SLE (APS-SLE),通常对传统的免疫抑制疗法表现出耐药性.
对于耐火性严重SLE患者,需要有效和安全的治疗选择.

研究的目的:

评估阿尼弗罗卢马布 (ANF) 在患有严重SLE的患者的疗效和安全性.
评估ANF在神经性SLE,狼性炎和APS-SLE患者中的有效性.
分析波兰队列中ANF治疗的真实世界临床数据.

主要方法:

对10名严重SLE患者的回顾性分析,这些患者接受了Anifrolumab (ANF) 治疗.
患者患有活跃的神经性SLE,狼性炎或APS-SLE,并且对先前高剂量免疫抑制疗法和葡萄糖皮质类固醇耐药.
收集的数据包括临床病史,人口统计,成像和SLEDAI-2K得分.

主要成果:

所有10名患有严重SLE症状的患者都经历了显著的临床改善.
在阿尼弗罗卢马布 (ANF) 治疗后观察到系统性狼红斑血病活动指数2000 (SLEDAI-2K) 得分的降低.
在这个队列中,阿尼弗罗卢马布 (ANF) 显示出了有利的安全概况.

结论:

阿尼弗罗卢马布 (ANF) 是严重SLE患者的一个有前途的治疗选择.
现实世界的数据支持阿尼弗罗卢马布 (ANF) 在SLE耐火病例中的疗效和安全性.
阿尼弗罗卢马布 (ANF) 为严重和复杂的SLE病例提供了潜在的新治疗途径.

关键词:

这样,我们就有了anifrolumab.狼性炎是一种神经炎症.这是神经精神病性狼.系统性红血性狼 (Systemic Lupus Erythematosus) 是一种全身性狼.

更多相关视频

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...